Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer
Table 2
Univariate and multivariate analysis of the relationship between programmed death ligand-1 expression and clinicopathological characteristics of pulmonary adenocarcinoma.
Clinical factors
Total
PD-L1 expression
Univariate analysis
Multivariate analysis
No.
%
Negative
Positive
OR (95% CI)
value
OR (95% CI)
value
319
100.0
228
71.5%
91
28.5%
Age (y)
1.13 (0.69–1.83)
0.632
<61
154
48.3
112
72.7%
42
27.3%
≥61
165
51.7
116
70.3%
49
29.7%
Sex
1.73 (1.06–2.84)
0.027
1.02 (0.48–2.19)
0.952
Male
151
47.3
99
65.6%
52
34.4%
Female
168
52.7
129
76.8%
39
23.2%
Reference
Smoking history
2.01 (1.21–3.33)
0.007
1.55 (0.71–3.37)
0.272
Never
215
67.4
164
76.3%
51
23.7%
Reference
Former/current
104
32.6
64
61.5%
40
38.5%
Size (cm)
1.24 (0.76–2.03)
0.396
<3.2
194
60.8
142
73.2%
52
26.8%
≥3.2
125
39.2
86
68.8%
39
31.2%
Pathological stage
1.35 (1.08–1.69)
0.008
0.70 (0.45–1.08)
0.110
I
186
58.3
145
78.0%
41
22.0%
II
37
11.6
23
62.2%
14
37.8%
III
68
21.3
42
61.8%
26
38.2%
IV
28
8.8
18
64.3%
10
35.7%
T stage
1.13 (0.87–1.48)
0.345
T1
176
55.2
133
75.6%
43
24.4%
T2
98
30.7
64
65.3%
34
34.7%
T3
22
6.9
13
59.1%
9
40.9%
T4
23
7.2
18
78.3%
5
21.7%
Lymph node metastases
2.83 (1.69–4.73)
<0.0001
3.01 (1.17–7.74)
0.022
N0
224
70.2
175
78.1%
49
21.9%
Reference
N1/N2/N3
95
29.8
53
55.8%
42
44.2%
Metastatic
1.44 (0.64–3.25)
0.380
M0
291
91.2
210
72.2%
81
27.8%
Reference
M1
28
8.8
18
64.3%
10
35.7%
SUVmax
9.07 (3.80–21.64)
<0.0001
7.52 (3.03–18.65)
<0.0001
<4.07
95
29.8
89
93.7%
6
6.3%
≥4.07
224
70.2
139
62.1%
85
37.9%
EGFR mutation status
2.10 (1.27–3.48)
0.004
1.77 (1.01–3.11)
0.046
Mutation
211
66.1
162
76.8%
49
23.2%
Reference
Wild type
108
33.9
66
61.1%
42
38.9%
PD-L1, programmed cell death ligand = 1 SUVmax, maximum standardized uptake value; EGFR, epidermal growth factor receptor.
